Boardroom Alpha
Boardroom Alpha
NUS · Current Report (Form 8-K) · Filed March 9, 2026

Nu Skin Enterprises Inc — Current Report (Form 8-K)

Form
8-K
Filed
March 9, 2026
Period
Mar 5, 2026
Ticker
NUS
Accession
0001140361-26-008469
Boardroom Alpha · Filing insights

Chayce D. Clark named EVP, COO and CLO; compensation and equity package disclosed.

About Nu Skin Enterprises Inc
Market cap
$272M
1Y TSR
−19.1%
3Y TSR
−40.7%
Board grade
C-
Sector
Consumer Defensive
CEO
Ryan S Napierski
Last annual meeting: May 28, 2026 · View full Nu Skin Enterprises Inc profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
March 5, 2026
 
 
Date of Report (Date of earliest event reported)
 
     
 
NU SKIN ENTERPRISES, INC.
 
 
(Exact name of registrant as specified in its charter)
 

Delaware
 
001-12421
 
87-0565309
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification Number)

 
75 West Center Street
Provo, Utah 84601
 
 
(Address of principal executive offices and zip code)
 
     
 
(801) 345-1000
 
 
(Registrant’s telephone number, including area code)
 
     
 
N/A
 
 
(Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c), (e)

On March 5, 2026, the Board of Directors of Nu Skin Enterprises, Inc. (the “Company”) appointed Chayce D. Clark as Executive Vice President, Chief Operating Officer and Chief Legal Officer.

Mr. Clark, age 43, has served as the Company’s Executive Vice President and General Counsel since 2021. Mr. Clark joined the Company in 2015 as Assistant General Counsel and later served as Vice President and Deputy General Counsel before beginning his role as General Counsel. Prior to joining the Company, he was a litigation attorney in private practice in Salt Lake City, Utah. He received a B.S. degree from Southern Utah University and a J.D. degree from the University of Utah.

In connection with his new role, Mr. Clark will have a base salary of $650,000, and his target annual bonus percentage will remain at 75% of base salary. His 2026 annual equity award will have a value of $2,362,500, consisting of 50% time-based restricted stock units (“RSUs”) and 50% performance-based restricted stock units (“PRSUs”). The RSUs will vest 25% in each of 2027, 2028, 2029 and 2030, and the PRSUs will vest, if at all, in three tranches based on the Company’s earnings per share in 2026, 2027 and 2028, respectively.

Mr. Clark does not have a family relationship with any of the Company’s directors or executive officers, and the Company does not have any reportable related-person transactions involving Mr. Clark. Other than as described herein, there are no arrangements or understandings between Mr. Clark and any other person pursuant to which Mr. Clark was selected as Executive Vice President, Chief Operating Officer and Chief Legal Officer.

A copy of the related press release, which the Company issued on March 9, 2026, is attached as Exhibit 99.1 hereto.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Nu Skin Enterprises’ press release dated March 9, 2026.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NU SKIN ENTERPRISES, INC.
 
(Registrant)
   
 
/s/ James D. Thomas
 
 
James D. Thomas
 
Chief Financial Officer
Date: March 9, 2026
 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Nu Skin Enterprises Inc (NUS)

Reference

Frequently asked questions

When did Nu Skin Enterprises Inc file this 8-K?
Nu Skin Enterprises Inc (NUS) filed this Current Report (Form 8-K) with the SEC on March 9, 2026. The accession number assigned by EDGAR is 0001140361-26-008469.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Chayce D. Clark named EVP, COO and CLO; compensation and equity package disclosed. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Nu Skin Enterprises Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Nu Skin Enterprises Inc has filed under CIK 1021561, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer